Is Erlotinib/Tarceva a targeted drug?

Erlotinib (Erlotinib) is a typical small molecule targeted drug. Its core mechanism of action is to selectively inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), thereby blocking the tumor cell proliferation signaling pathway. This precise intervention mechanism makes erlotinib different from traditional chemotherapy drugs. It does not rely on non-specific cytotoxicity, but achieves anti-tumor effects by intervening in specific signaling networks at the molecular level. Therefore, clinically, erlotinib is classified as an EGFR targeted drug. It is mainly suitable for the subgroup of patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations. It also shows potential value in the adjuvant regimen for some solid tumors such as pancreatic cancer.

One of the characteristics of targeted drugs is that they can relatively reduce damage to normal cells while inhibiting the proliferation of cancer cells. This also explains why oral administration of erlotinib can achieve long-term maintenance treatment without the need for frequent infusions or the risk of significant bone marrow suppression like traditional chemotherapy. Overseas guidelines and clinical practice have emphasized that EGFR mutation detection is a key link in determining whether a patient is suitable for erlotinib treatment. This is also the core embodiment of the targeted therapy concept: individualized treatment through molecular markers.

Although erlotinib has obvious efficacy, its side effects still need to be paid attention to, especially skin reactions, gastrointestinal discomfort and a small number of interstitial pneumonia. Doctors usually conduct evaluation and long-term follow-up management before prescribing the drug. In short, from the perspective of mechanism of action, clinical application and individualized treatment, erlotinib is indeed a targeted drug. It is one of the preferred precision intervention options for patients with EGFR mutated advanced non-small cell lung cancer. It is also a representative drug of small molecule oral targeted drugs in the modern tumor treatment system. It has both convenience and accuracy, and is in line with the concept of precision medicine.

References: https://en.wikipedia.org/wiki/Erlotinib